Breaking down the barriers: fMRI applications in pain, analgesia and analgesics by Borsook, David & Becerra, Lino R
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
Molecular Pain
Open Access Review
Breaking down the barriers: fMRI applications in pain, analgesia and 
analgesics
David Borsook*1,2 and Lino R Becerra1
Address: 1P.A.I.N. Group, Brain Imaging Center, Department of Psychiatry, McLean Hospital, Belmont, MA, USA and 2Athinoula Martinos Center 
for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Email: David Borsook* - dborsook@mclean.harvard.edu; Lino R Becerra - lbecerra@mclean.harvard.edu
* Corresponding author    
Abstract
This review summarizes functional magnetic resonance imaging (fMRI) findings that have informed
our current understanding of pain, analgesia and related phenomena, and discusses the potential
role of fMRI in improved therapeutic approaches to pain. It is divided into 3 main sections: (1) fMRI
studies of acute and chronic pain. Physiological studies of pain have found numerous regions of the
brain to be involved in the interpretation of the 'pain experience'; studies in chronic pain conditions
have identified a significant CNS component; and fMRI studies of surrogate models of chronic pain
are also being used to further this understanding. (2) fMRI studies of endogenous pain processing
including placebo, empathy, attention or cognitive modulation of pain. (3) The use of fMRI to
evaluate the effects of analgesics on brain function in acute and chronic pain. fMRI has already
provided novel insights into the neurobiology of pain. These insights should significantly advance
therapeutic approaches to chronic pain.
Background: 'O (Chronic) Pain Miserum'
At least two major hurdles remain in the treatment of
chronic pain. The first is that no objective test for pain cur-
rently exists. A blood test, genetic marker or psychophysi-
cal measure would greatly improve diagnosis of chronic
pain. The second is the lack of an "antibiotic equivalent"
(i.e., drugs with high sensitivity and specificity) for the
treatment of chronic pain subtypes (e.g., neuropathic
pain). Controlled trials of drug efficacy indicate that, on
average, the most effective drugs of different classes have
similar efficacy (around 30% greater than placebo) across
neuropathic conditions [1-3]. Analgesic use is dictated by
both efficacy and adverse side effects and side effects can
sometimes take precedence over efficacy [4]. A lack of con-
trolled trials for other methods of pain treatment (inter-
ventional, psychological, physical therapy) makes it
difficult for physicians to evaluate these possible thera-
pies. As a result, chronic pain treatment is difficult, and
physicians and patients often resort to using multiple
treatments simultaneously or sequentially in the effort to
achieve pain relief. Unfortunately, even a combined ther-
apeutic approach frequently offers little benefit (Figure 1).
Recent advances in functional imaging have revolution-
ized our concept of central process of pain. Indeed, it
seems that we are on the verge of using this technology to
reach a fundamental new understanding of clinical pain,
particularly chronic pain (defined as pain lasting for more
than 6 months). Subdivision of chronic pain syndromes
into chronic neuropathic pain (e.g., phantom pain, post-
herpetic neuralgia), chronic nociceptive pain (e.g., arthri-
tis, migraine), and a group comprising very poorly under-
stood categories of pain (e.g., fibromyalgia, depression-
induced pain, or complex regional pain syndrome) has
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not clarified mechanistic processes. Even classification of
chronic pain types based on clinical disease (e.g., cancer
pain, diabetic pain) has not proved very helpful in under-
standing the mechanisms underlying chronic pain.
Recently a mechanistic approach to defining pain has
been suggested in which specific pain phenotypes such as
shooting pain, burning pain, and allodynia can be
applied across pain types such as neuropathic pain. [5].
However, this approach is based primarily on an under-
standing of peripheral nerve and spinal cord processing.
Functional imaging has already redefined chronic pain as
a degenerative disease, and has shed some light on com-
plex diseases such as fibromyalgia [6]. Since brain
responses are the final common pathway in behavioral
responses to pain (unconscious and conscious), we
believe that the application of functional imaging will
allow us to categorize pain conditions in an objective
manner and to better understand the underlying circuitry
and identify targets for a new generation of analgesics
[7,8].
fMRI measures neural activity by an indirect evaluation of
changes in blood flow in capillary beds [9]. A number of
approaches including block design [10], event-related
[11], and percept-related. [12] paradigms, have been
applied to fMRI studies of physiological, clinical and
pharmacological aspects of pain and analgesia. Applica-
tion of baseline measures of spontaneous pain have
allowed the "basal state" to be evaluated.) [13]. Issues per-
taining to the validity of fMRI in pain and analgesic meas-
ures have been presented elsewhere [14].
"To consider only the sensory features of pain, and ignore its
motivational and affective properties, is to look at only part
of the problem, not even the most important part at that."
This statement of Melzack and Casey's [15] was an early
recognition of these aspects of pain, but their importance
is now widely accepted. The ability to use fMRI to image
the whole brain at the same time and to use powerful
algorithms to segregate functional circuits allows us to
begin to elucidate the CNS processes underlying affective
and motivational components of pain. It also allows a
broader window to observe potential CNS sites of drug
action. Our understanding of 'difficult' disease states (e.g.,
fibromyalgia or depression-related pain), the placebo
response, emotional responses (e.g., empathy), and acu-
puncture will clearly be influenced by new insights into
how emotional circuitry in the brain functions in pain
states and in responses to analgesics. [16]. In this paper,
we review the contribution of fMRI to the understanding
of acute and chronic pain, its use in surrogate models and
for evaluation of endogenous pain systems including the
placebo response, and its potential use as an objective
measure of analgesic efficacy. The approach we have taken
to summarize the new advances has been to provide an
overview for each domain (e.g., Acute and Chronic pain,
Endogenous Systems etc.) and summary tables that focus
on specific areas within each domain (e.g., Chronic pain:
The problem with chronic pain Figure 1
The problem with chronic pain. Therapy for acute pain (e.g., acute inflammation, trauma, post-surgical pain) is overall 
excellent. However, in chronic pain (e.g., neuropathic pain, fibromyalgia, complex regional pain syndrome), therapy is poor. 
This group thus falls into a zone (circles) of "therapeutic failure" or "therapeutic impasse" where multiple therapies are tried 
with overall little success. Functional imaging appears poised to open up new approaches to the understanding of chronic pain 
conditions. An improved basic understanding of the mechanisms underlying chronic pain is likely to suggest new avenues for 
the development of novel pharmacotherapies.
Drug Efficacy
Pain
Acute
Pain with 
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Neuropathic, Fibromyalgia etc.). Studies listed are pre-
dominantly from peer-reviewed journals (Data Sources:
Medline) or data from our own lab presented at Society
for Neuroscience and/or in press. We attempted to include
primary examples on specific entities of CNS processing as
defined with fMRI that are related to pain, analgesia and
analgesics.
Advancing our Understanding of CNS 
Mechanisms in Acute and Chronic Pain through 
fMRI
fMRI of Physiological Pain – a new understanding of
brain regionsinvolved in pain processing in humans
Much of the work in fMRI of pain has utilized thermal
stimuli (contact peltier thermodes or laser) to activate
pain circuits. Other types of stimuli, including electrical
and mechanical (pressure) have not been as extensively
used either in the intact system or where sensitization has
been experimentally induced (see Table 3). The accumu-
lation of data has begun to identify brain regions involved
in pain processing – from peripheral ganglia to central
limbic and brainstem structures previously only impli-
cated in animal studies in the preclinical literature (see
Table 1).
Some of these regions are part of well-defined pain circuits
(e.g., PAG, parabrachial nuclei) while for others such as
the nucleus accumbens, their specific role in pain process-
ing is not well understood [17,18]. Studies have reported
specificity of somatotopic organization of structures out-
side of the primary somatosensory cortex involved in pain
processing in humans; these such as the insula [19] and
the trigeminal system [14,20]. Indeed, the results of
human imaging help focus attention on specific regions,
including the nucleus accumbens (involved in emotional
salience), the insula (involved in specific interpretation of
noxious stimuli) or the amygdala (involved in fear),
opening new vistas for understanding how the human
brain evaluates pain. The ability to evaluate activity and
organize active regions into neural circuits that subserve
specific pain/analgesia functions (i.e., sensory, emotional,
autonomic, endogenous analgesic circuits) is a step for-
ward. A number of studies have already begun this task
including segregation of function within a structure (e.g.,
PAG [17] and NAc [18]), defining analgesia as a rewarding
process [21], and functional differentiation of activation
sites within a particular brain region (e.g., cognitive and
affective regions within the anterior cingulate [17]).
What is needed now is to further evaluate these brain
areas, some of whose role is newly defined in pain
processing in humans, at a functional level. Several new
fMRI approaches will aid this effort including techniques
that allow definition of large scale systems organization
[22]; techniques that define circuits/functional connectiv-
ity [23]; and automated parcellation of brain structures
[24,25] including the thalamus [26]. Imaging studies have
not only unveiled new regions involved in pain process-
ing, but have also contributed new insights into the func-
tioning of these regions in experimental pain. For
example, the hippocampus, classically associated with
memory, has been shown to be involved in pain-induced
anxiety [27-29].
fMRI of Chronic Pain
Imaging clinical conditions is fraught with issues that
make it more challenging, including the fact that it is dif-
ficult to assemble a cohort with similar symptoms, dura-
tion of disease, medication history, age distribution, etc.
Among clinical conditions, chronic pain has a particularly
wide spectrum of patient presentations and medical histo-
ries. However, studies have begun to evaluate CNS
changes that occur in patients with chronic pain (see
review by Apkarian and colleagues [30]), including those
with neuropathic pain, fibromyalgia, complex regional
pain syndrome and visceral pain (Table 2).
A number of important issues are emerging in the evalua-
tion of chronic pain conditions as fMRI and associated
imaging technologies become more sophisticated.
Chronic pain produces changes that become manifest as
alterations in the central nervous system. One may term
this "centralization of hyperalgesia" or "centralization of
pain". This has been evaluated across diseases including
fibromyalgia [6], chronic back pain [31], and irritable
bowel syndrome [32]. During functional imaging of
fibromyalgia and chronic back pain, enhanced responses
to thermal or mechanical stimuli that are applied hetero-
topically (i.e., away from the actual location of the pain)
are present in a number of CNS regions, including non-
sensory regions. Differences in specific responses to
brush, heat and cold in affected vs. intact regions in
patients with neuropathic pain have also been reported
[33]. One feature that seems to be of in common with
chronic pain patients is significantly greater frontal lobe
activation in chronic pain sufferers [30]. This feature, sug-
gests that in chronic pain CNS activity in regions involved
in cognitive processing differs between acute and chronic
pain. These insights are further complicated by the new
and revolutionary recognition that, in chronic pain, neu-
ronal loss occurs in significant pain pathways including
the thalamus and the lateral prefrontal cortex [34]. The
role of this neurodegeneration in producing either the
altered CNS responses or the pain state is not understood.
Maladaptative changes in non-sensory circuits may con-
tribute to the psychological states, including depression,
anxiety and amotivation that are often seen in these
patients. Thus the study of specific brain regions such asM
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Table 1: Examples of Contributions by fMRI on the understanding Brain Regions activated by Acute Pain
STUDY FOCUS REFERENCE MAJOR FINDINGS COMMENT
Peripheral Nerve
Trigeminal Ganglion (TG) Borsook et al., 2003. [63] Somatotopic activation in the trigeminal ganglion Measures of the peripheral nervous system may be 
evaluated using fMRI
Dorsal Horn
Trigeminal Nucleus (TN) DaSilva et al., 2002. [20] Somatotopic acitivation in the TN Study reports that pain spinal cord brainstem systems can 
be defined and somatotopically evaluated.
Brainstem
Periaqueductal Gray (PAG) Becerra et al., 2001 [17] Both increases (early) and decrease (late) of activation 
may correlate with ascending and descending 
(modulatory) components of functioning within this 
structure.
The PAG is a 'core' structure in understanding how the 
brain modulates pain, both in placebo and in the effects of 
analgesics, particularly opioids.
Right Cuneus Fulbright et al., 2001 [64] Cold pressor induced pain produced activation in a 
number of regions including the frontal lobe and the 
cuneus.
Measures of affective components of cold pain.
Brainstem NucleiCuneiformis, 
parabrachial, PAG, red nucleus
Dunckley et al., 2005 [65] Activation to somatic and visceral pain. A big step forward in measures of brainstem measures of 
pain in humans. Marked similarities in the two processes 
were observed at a brainstem level.
Subcortical Gray Regions
Emotion CircuitryAccumbens, 
SLEA, Amygdala, Hippocampus, 
Hypothalamus, Oribitofrontal 
Cortex
Becerra et al., 2001 [17] Acute pain activates circuitry that is commonly associated 
with reward. Emotional circuitry is activated ahead of 
sensory circuitry
The first demonstration that reward circuitry can be 
mapped in acute pain.M
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Amygdala Seymour et al., 2005 [21] Termination of pain (rewarding) activates the amygdala The significance of understanding the brain systems to 
natural reward (i.e., pain relief).
Putamen Bingel et al., 2004 [66] 15 Subjects. Laser evoked pain to foot or hand produced 
contralateral somatotopic organization in putamen
Clear activation in putamen by pain indicative of potential 
role in emotional or motor processing of pain.
Accumbens (NAc) Aharon et al., 2006 [18] Acute noxious (but not non-noxious) stimuli activate the 
NAc. Within the structure, different signals may indicate 
functional processing within the 'core' and 'shell' of the 
structure.
A number of regions have different functional 
components (e.g., amygdala, PAG) and the ability to 
dissect apart these within a set paradigm will contribute 
further to mechanistic functions of pain processing in 
humans.
Cortical Regions
Anterior Cingulate(aCG) Becerra et al., 1999 [10], 2001 [17] One of the first fMRI studies to demonstrate differential 
aCG activation in the structure.
Differentiation of sensory vs. emotional components of 
aCG function.
Hippocampus (Hi) Ploghaus et al., 1999 [27], 2000 [67], 2001 [28] Hippocampal activation correlates with anxiety/ Papers address a specific function of the hippocampus in 
pain and further show a correlation with insula activity.
Insula (I) Brooks et al., 2005. [19] Somatotopic organization in the insula defined The insula has been a bit of an enigma. Based on 
preclinical work, human work seems to support the 
notion that the insula is receives thermal information 
from the ventromedial nucleus of the thalamus (VMpo) 
specific thermal stimuli
Oribtofrontal Cortex (GOb) Rolls et al., 2003. [68] Effects of pleasant and painful touch to hand. 
Oribitofrontal activation > pleasant or pain vs. neutral. SI 
less activated by pleasant and pain than neutral touch. 
Regional differences in aCG to pleasant (rostral aCG) and 
pain (posterior dorsal). Brainstem (e.g., PAG) activated by 
all 3 touch stimuli.
Clear dissociation between sensory and emotional 
systems to 'reward' and aversion.
Somatosensory Cortex Bingel et al., 2004 [66] Painful laser stimuli applied to hand and foot produced 
somatotopic organization in contralateral and ipsilateral SI 
cortex.
Laser stimuli can provide stimuli without tactile 
components.
Table 1: Examples of Contributions by fMRI on the understanding Brain Regions activated by Acute Pain (Continued)M
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Table 2: Examples of Contributions of fMRI to the understanding of CNS circuitry underlying Chronic Pain
STUDY FOCUS REFERENCE MAJOR FINDINGS COMMENT
Neuropathic Pain
Mechanical Allodynia Peyron et al., 2004. [69] Activated regions mirror control network activated by brush, 
cold to the normal side. Regions activated include SI, SII and 
insula.
Study tackles an issue of ongoing pain and the problems 
associated with ongoing background pain.
Back Pain vs. Postherpetic 
Neuropathy
Apkarian et al., 2004. [34] A potentially huge step forward in the use of fMRI to 
differentiate chronic pain subtypes.
Trigeminal Neuropathy Becerra et al., 2005 [33] Becerra 
et al., 2006 [70]
V2 neuropathy patients evaluated in a repeat study for 
mechanical (brush) and thermal (cold and heat) stimuli.
Mechanistic changes in CNS function to specific stimuli.
Chronic Back Pain Giesecke et al., 2004. [31] Heterotopic pressure stimulus applied to the thumb activates a 
number of brain regions.
Generalized increase in pain sensitivity in chronic pain; pain >> 
in patients than controls for the same pressure stimulus. Equally 
painful stimuli produced similar brain activations.
Spinal Cord Injury (SCI) Nicotra et al., 2005 [71] Seven patients with SCI evaluated including painful stimuli 
(shock) in an aversive paradigm. Conditioning stimuli produces 
enhancement of activity in dorsal anterior cingulated, PAG and 
superior temporal gyrus to conditioning stimuli and attenuation 
in subgenual aCG, ventromedial prefrontal and posterior 
cingulated to threat of shock.
The study is able to dissect apart possible changes in the brains 
of SCI patients, including central sensitization and alterations in 
affective components of the brain (subgenual aCG) that may be 
part of a disturbance of affective and autonomic processing.
Unpleasant Odor Villemure et al., 2005 [72] Single patient with neuropathic pain where pain increased when 
exposed to experimental odors in thalamus, amygdala, aCG and 
SI.
This study may suggest subcortical mechanisms of aversion have 
a common neural circuitry.
Complex Regional Pain 
Syndrome
Pediatric CRPS Lebel et al., 2005. [73] Pediatric group with relapsing CRPS of lower extremity. 
Changes to cold most predominant.
Clinical models within particular groups of diagnosis may be 
used to determine the etiology of more chronic conditions e.g., 
adult CRPS.
Mechanical Allodynia in Adult 
CRPS
Maihofner et al., 2005 [40] Twelve Patients. Pin-prick hyperalgesia activates a number of 
cortical regions (SI, SII, Insula, aCG, frontal cortex).
Study focus is on cortical regions only and indicates significant 
changes in functioning in affected vs., unaffected. No control 
group.M
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Sympathetically Maintained Pain 
(SMP)
Apkarian et al., 2001. [74] Evaluation of stimuli to painful site before and after sympathetic 
blockade. SMP associated with increased prefrontal, aCG 
activation and decrease in contralateral thalamus.
Correlates of CNS function shown:ineffective blocks did not 
change cortical activityplacebo response same as effective block
Fibromyalgia
Primary fibromyalgia (FM) Cook et al., 2004 [75] Fibromyalgia compared with control group. Fibromyalgia group 
more sensitive on psychophysical evaluation. Non-painful stimuli 
produced greater activation in a number of regions including 
prefrontal, SMA, insula and cingulated cortices. Pain produced 
greater activation in the contralateral insula in (FM) patients.
Central changes with increased sensitivity/hyperalgesia are 
clearly manifest behaviorally and on fMRI. Such insights provide a 
new approach to understanding a heretofore ill- defined disease.
Catastrophizing Gracely et al., 2004 [6] Pressure stimulus applied to the thumb (i.e., heterotopic). SII 
activation >> in high catasrophizers; contralateral aCG and 
bilateral lentiform nucleus. This was independent of depression.
Catastrophizing may contribute to the pain state by enhancing 
the emotional reaction to pain.
Visceral Pain
Functional bowel disorder Kwan et al., 2005 [76] Healthy (11) vs. Patients (9) underwent painful rectal distention. 
Activation in the medial thalamus, hippocampus for pain.
On line ratings of pain responses. – clear differences in 
emotional circuitry of medial thalamus and hippocampus.
Irritable Bowel Syndrome (IBS) 
with constipation vs. diarrhea
Wilder-Smith et al., 2004 [77] Female healthy (10) and IBS (10; 5-constipated and 5-diarrhea) 
underwent rectal distention and painful heterotopic pain applied 
to activate DNIC. Significant differences in CNS regions 
(prefrontal cortex, amygdala, aCG, PAG, Hippocampus) 
between constipated and diarrhea groups and controls.
Different responses in patient subtypes of IBS suggesting 
differences in endogenous modulatory systems.
Irritable Bowel Syndrome (IBS) Mertz et al., 2000 [78] Healthy (16) vs. patients with IBS (18), IBS patients have 
increased activation in aCG.
Increased central sensitivity to the same type of stimulus.
Visceral and Cutaneous 
Hypersensitivity in Irritable Bowel 
Syndrome (IBS)
Verne et al., 2003 [32] Rectal cutaneous pain produced increased activation in thalamus 
and SI, I, aCG, pCG and prefrontal cortex.
The brain is adversely affected in chronic pain – both visceral 
and cutaneous hyperalgesia produced. These findings provide a 
window on how we may address treatments for these patients.
Irritable Bowel Syndrome (IBS) Bonaz et al., 2002. [79] Rectal pain produced in 11 female subjects with IBS. Activation 
in insula, amygdala and striatal regions. Greater activation in 
patients in the insula and frontal regions.
Similar to other studies a more complex alteration in pain 
processing is present in this group of subjects. Issues of 
variability in patients are still a concern.
Chronic Inflammation
Vulvar vestibulitis Pukall et al, 2005. [80] Allodynia measured in patients (14) and controls (14) age and 
contraceptive matched.
Similar type of changes in patients with IBS, Fibromyalgia.
Table 2: Examples of Contributions of fMRI to the understanding of CNS circuitry underlying Chronic Pain (Continued)Molecular Pain 2006, 2:30 http://www.molecularpain.com/content/2/1/30
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the nucleus accumbens (involved in probability assess-
ments and reward evaluation), the amygdala (involved in
orientating to and the memory of motivationally salient
stimuli), the hippocampus (involved in evaluating the
expectancy of an unknown condition), the prefrontal cor-
tex (involved in cognitive and planning functions around
emotional stimuli or regarding rewarding or aversive out-
comes) and the anterior cingulated cortex (involved in the
rank ordering of the value or salience of the stimulus) may
provide new insights into brain functioning in these co-
morbid conditions. Such insights should provide imme-
diate benefits to the understanding of the calcitrant nature
of chronic pain to therapeutic interventions.
Our increased recognition that multiple neural systems
are involved in pain processing and affect pain perception
(reward/aversion circuitry, the role of anticipation, neural
systems interpreting different pain types albeit at the same
intensity, opponent systems and drug effects) suggests
that multiple neural circuitries are likely affected in
chronic pain. Results published thus far indicate that: (1)
Pain intensity is probably not a good marker for changes
in chronic pain state. Neural imaging may be able to
define a correlation between CNS activation and patient
answers to a simple subjective questionnaire that assesses
emotional and other components of pain and suffering;
(2) Neural systems interpreting components of the pain
response (e.g., emotional, empathy, anticipation etc.) are
clearly complex, and we still have no understanding of
how these may change in the chronic pain condition; and
(3) Standards will need to be applied across imaging facil-
ities in order to interpret and compare data across studies.
fMRI of Human Surrogate Pain Models
Defining valid surrogate models has been a problem in
both animal and human models of pain [35-37]. In
human studies, mechanical (heat) or chemical (capsaicin)
sensitization of skin and testing in primary and secondary
regions affected has been used as a surrogate for neuro-
pathic pain (hyperalgesia/allodynia to thermal and
mechanical stimuli) [38]. Recently fMRI has been used to
evaluate the capsaicin – induced hyperalgesia model (see
Table 3). While many of these studies report increased
activation in a number of brain regions, some of the more
recent studies begin to define the utility of fMRI in dissect-
ing mechanistic changes or insights using this model [39-
41]. These studies demonstrate differences in brain activa-
tion in response to stimuli of equivalent pain intensity
delivered in sensitized vs. non-sensitized state, providing
further evidence that pain intensity by itself is probably
not a useful measure of the status of the underlying pain
processing circuitry [41]. An alternate explanation may be
that there are mechanistic differences between these two
states. Changes in perceived pain intensity may reflect
acute changes in CNS sensory pathways but may not cor-
relate with changes in CNS emotional pathways which
may be relevant to an individuals' overall response to pain
and may predict future pain conditions. Eventually, fMRI
should allow the direct comparison of activation in spe-
cific CNS regions in experimental models with the activa-
tion seen in patients with neuropathic pain. Comparing
such objective measures should allow us to determine
where the model differs from the disease and to assess the
validity of such models for evaluating potential therapies.
fMRI studies of Endogenous Analgesia
Endogenous modulatory networks can either facilitate or
inhibit pain[42,43]. Endogenous analgesia refers to sys-
tems that produce the latter. These systems involve a net-
work that includes higher cortical (e.g., anterior cingulate
cortex) and subcortical regions (e.g., the amygdala,
hypothalamus) that project to brainstem nuclei (periaq-
ueductal gray and raphe nuclei) that send projections to
the dorsal horn [44] These systems can be modulated by
a number of factors including stress, pain and the placebo
response [42].
A number of studies have used fMRI to investigate endog-
enous modulation of pain (Table 4) and map circuits
involved in CNS systems that can alter decrease or
increase pain [45-47]. Most of these studies involved
attention or distraction to modulate circuits. In addition,
closely linked with this are studies of placebo response,
evaluation of the effects of attention and expectancy, of
empathetic reactions to pain in others, to producing
"trickery" of the brain by sensory inputs [48].
Perhaps of greatest importance are studies of the placebo
effect since there has been a significant literature in this
domain from psychophysical studies [49,50]. A neurobi-
ology and neurocircuitry were predicted for the placebo
effect based on its effects on analgesia. [51]. Indeed the
general circuitry of the placebo response can be applied to
non-painful stimuli. These and other studies have
enhanced our knowledge of the interaction of physiolog-
ical pain circuits and cognitive/emotional circuits [52].
The use of imaging has now clearly established how some
of these endogenous systems operate. This understanding
coupled with an objective method of evaluating placebo
should provide novel insights into drug development as
well as the treatment of patients with acute and chronic
pain.
Complementary with fMRI studies on placebo, the use of
fMRI has identified neural systems involved in anxiety
and fear related to pain. These two reactions to pain are
important both from a neuroscience aspect. [16] as well as
from practical applications of treating patients. While fear
and anxiety have been considered to have different effectsMolecular Pain 2006, 2:30 http://www.molecularpain.com/content/2/1/30
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on neural processing [53], recent fMRI studies have begun
to explore this issue [54].
The innate nature of the pain experience is clearly indi-
cated by studies showing that activations in non-sensory
CNS systems in an observer experiencing empathetic pain,
are similar to those produced in a subject by noxious stim-
uli. The study of endogenous analgesia highlights the
opponent systems operating in pain. In addition, fMRI
studies reveal that in addition to the sensory pathways
activated in endogenous analgesia and pain processing,
reward/aversion circuitry is activated, with reward related
to pain relief and aversion related to pain. [21]. The bal-
ance between these opponent systems may be crucial in
determining the overall sensory and emotional experience
of pain in chronic pain states.
fMRI has also been applied to exploring the neurobiology
of acupuncture, which is believed to activate endogenous
analgesic mechanisms [55]. Such studies have predomi-
nantly been in healthy subjects using experimental pain.
The evidence for the benefit of acupuncture for clinical
studies has been mixed. For example, recent studies in
migraine patients has indicated that acupuncture may be
no more effective than sham acupuncture in reducing
migraine headaches, although both are more effective
than no intervention. Such studies need to be repeated,
but raise questions as to how acupuncture works (for
example, through activation of diffuse noxious inhibitory
controls or activation of endogenous systems through
expectancy etc.) [56]. In carefully devised studies, defining
brain circuits involved in expectancy, treatment etc. may
help provide a more objective evaluation of such interven-
tions.
fMRI Studies of Analgesics
fMRI is also being applied to the evaluation of analgesics
(pharmacological MRI or phMRI). [57]. Examples are pro-
vided in Table 5.
Analgesic effects on brain systems or neural circuits (stim-
ulus independent) – Many analgesics have direct CNS
effects, and very little is known about how they act on the
human brain. Such studies are most often performed in
healthy volunteers. Here the direct effect of administra-
tion of a drug is observed without any stimulus paradigm.
Table 3: Examples fMRI Studies of Surrogate Models of Pain
STUDY FOCUS REFERENCE MAJOR FINDINGS COMMENT
Experimental Allodynia
Capsaicin induced 
secondary hyperalgesia
Baron et al., 1999 [81] 9 Subjects. Capsaicin injection induced 
secondary mechanical hyperalgesia. Painful 
mechanical stimulation produced activation 
in prefrontal cortex >> than in nonpainful 
mechanical stimulation
First fMRI study of capsaicin induced 
hypersensitivity. Activation in 
prefrontal cortex = attention and 
cogniitvie changes (e.g., planning).
Brainstem activation by 
capsaicin
Zambreanu et al., 2005 [82] Heat-capsaicin model used. Punctate 
mechanical stimuli applied to region of 
secondary hyperalgesia. Stimuli in 
hyperalgesic vs. control region showed 
activation in contralateral brainstem, 
cerebellum, bilateral thalamus, contralateral 
SI and SII, middle frontal gyrus, parietal 
association cortex and brainstem 
(cuneiformis, superior colliculi, PAG.
First evaluation of contribution of 
brainstem in central sensitization.
Cognitive influences on 
hyperalgesia
Wiech et al., 2005. [83] Capsaicin-induced heat hyperalgesia results 
in frontal and medial prefrontal cortex, 
insula, and cerebellum. Activity in medial 
prefrontal cortex and cerebellum 
modulated by cognitive task.
Study addresses interaction between 
motivational and cognitive functions 
and may provide some basis for 
evaluating similar changes in chronic 
pain.
Capsaicin allodynia Maihofner et al., 2004. [39] Region of allodynia produced by capsaicin 
and thermal kindling. Brush to normal skin 
results in SI, parietal association cortex, SII 
bilaterally, contralateral insula. Brush to 
allodynic skin resulted in some overlap to 
those observed for control in addition to 
inferior frontal cortex, and ipsilateral insula.
Subtraction (unaffected vs. affected 
skin) indicates that mechanical allodynia 
in regions that include SI, parietal 
association cortex, inferior frontal 
cortex, and insula.
Definitions of terms in Table 3:
Allodynia – pain to a normally non-noxious stimulus.
Central Sensitization – increased sensitivity or excitability in central pain pathways as a result of increase in sensitivity/activation of these neural 
systems
Hyperalgesia – An increased response to a stimulus that is normally painful
Secondary Hyperalgesia – pain outside of the area of the primary injury.M
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Table 4: Examples of Contributions of fMRI on Endogenous Mechanisms of Pain or Analgesia
STUDY FOCUS REFERENCE MAJOR FINDINGS COMMENT
Placebo
Placebo Wager et al., 2004 [49] 2 studies report that (1) placebo analgesia decreased activation in 
thalamus, insula aCG and (2) anticipation increased activation in 
prefrontal cortex
Placebo analgesia may not only decrease pain but may change the 
affective response to pain.
Placebo in Emotional Processing Petrovic et al., 2005 [84] Use of pleasant and unpleasant pictures compared with pain. The 
same modulatory effect is observed in "emotional" placebo and 
placebo analgesia (anterior cingulated, lateral orbitofrontal cortex)
Placebo is a process in reward processing.
Placebo analgesia Bingel et al., 2006 [85] Nineteen healthy subjects. Placebo analgesia using laser for pain 
stimulation shows interaction between aCG, amygdala and PAG
Interactions between emotional circuits including the aCG amygdala 
and affect output processing of endogenous pain control mechanisms.
Attention
Attentional modulation Tracey et al., 2002 [46] Nine Subjects. Distraction during painful thermal stimulus. Pain ratings 
significantly lower with distraction with increased activation in the 
PAG during this condition.
Specific output of modulatory system via a well-known brain region 
(i.e., PAG) presumably via inputs from higher cortical regions.
Distraction Valet et al., 2004 [47] Stroop task used for distraction during noxious and innocuous heat 
stimuli. Distraction produced decreases in VAS pain intensity and 
unpleasantness scores. Distraction increased activation in 
orbitofrontal cortex, perigenual aCG, PAG and posterior thalamus.
Covariate analysis indicated that the brain may gate information by 
exerting a top-down effect on PAG and posterior thalamus.
Cognitive Distraction Task Bantick et al., 2002 [86] Stroop task used. Intermittent thermal pain applied. Distraction 
produced increased activation in affective region of the aCG and in the 
Gob, but decreased activation in pain sensory regions including the 
cognitive area of the aCG, insula, and thalamus.
Dissection of the effects of distraction on emotional/affective vs. 
sensory systems in a distraction paradigm.
Virtual Reality Distraction Hoffman et al., 2004. [87] Virtual reality decreased pain; both psychophysical ratings and brain 
activity in aCG, SI, SII, insula and thalamus.
Distraction has not been used in fMRI studies of chronic pain.
Attention to 'location' and 
'unpleasantness'
Kulkarni et al., 2005 [88] Attention to location – activity in SI and inferior parietal cortex. 
Attention to unpleasantness – activation reported in aCG, 
orbitofrontal and frontal cortex, amygdala, hypothalamus and
Study focus is on how attention can significantly modulate pain 
processing.
Miscellaneous
Empathy pain activates affective 
but not sensory pain
Singer et al., 2004. [89] Empathy evaluated by subject in magnet observing loved one receive 
similar painful stimulus (empathetic pain). Activation in insular, aCG, 
brainstem and cerebellum by both direct or empathetic pain.
Activation in affective circuits not sensory – this may be further 
support for affective circuits being a focus of study in chronic pain.
Pain and Social Loss Panksepp, 2003 [90] Evaluation of social exclusion (rejection). Activation in aCG and 
ventral prefrontal cortex > with exclusions
Commonality of physical pain response and emotional rejection/hurt?
Salience of Painful Stimuli Downar et al., 2003 [91] Sustained pain and non-painful electrical stimulation. Transient 
activation during 'on' and 'off' of non-painful stimuli in aCG, inferior 
frontal, temporoparietal regions to non-painful. Same regions in 
addition to thalamus and putamen showed sustained response during 
painful stimulus.
Basal ganglia play a role in sustained salience.
Expectancy orAnticipation
Dissociation of pain from its 
anticipation
Ploghaus et al., 1999 [27] Expectation of pain produced activation in medial frontal region, 
insula, and cerebellum. These differed from pain experience.
Emotional/cognitive evaluation of a situation can produce adaptation 
that can modify the experience. This has enormous implications in the 
clinical situation e.g., anticipating a procedure. Effects in or on chronic 
pain are unknown.M
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Expectation of Pain Sawamoto et al., 2000 
[92]
Expectation increases response to non-painful stimuli in the aCG and 
posterior insula.
Pain/unpleasantness and pain relief may be opponent processing using 
similar circuitry.
Expectation of Pain Relief Seymour et al., 2005. [21] Activation in the amygdala and midbrain by pain are mirrored by 
opposite aversion signals in the lateral orbitofrontal cortex and aCG.
Expected vs. Experience Pain Koyama et al., 2005. [93] Pain intensity to expected vs. experienced pain evaluated. With 
increased level of expected pain, activation increased in aCG, insula, 
thalamus, and prefrontal cortex. Pain experience produced activation 
in a number of regions (partial overlap with expectancy related pain).
Expectation can modulate the actual experience.
Anticipation of pain Porro et al., 2002 [94] Expectation of a pain/no pain stimulus to the foot. Activations 
increased in contralateral SI but decreased in ipsilateral SI, aCG.
Focus on cortical system
Hypnotically induced (HI) or 
imagined pain
Derbyshire et al., 2004. 
[95]
HI pain produced activation in thalamus, aCG, I, prefrontal and 
parietal cortices.
Pain pathways can be activated without a noxious stimulus. This has 
implications for understanding CNS processing in chronic pain 
disorders with no specific etiology.
Expectancy using a conditioning 
cue
Keltner et al,. 2006 [45] Pain intensity expectancy acts via a modulatory network that 
converges on the nucleus cuneiformis (nCF)
A study defining a specific modulatory pathway on this brainstem 
nucleus.
Paradoxical Sensations
Paradoxical heat Davis et al., 2004. [48] When subjects perceived a painful stimulus even though the stimulus 
was cool or neutral, activation in the right insular cortex was 
observed.
Sensory inputs in the normal healthy condition can "confuse" the 
brain. Such insights will be helpful in understanding pain processing in 
chronic conditions, particularly neuropathic pain.
Prickle sensation Davis et al., 2002. [12] Prickle sensation using cold, produced activations present in pain, 
motor and sensory areas. aCG, SII, prefrontal cortex, caudate, 
dorsomedial thalamus, prefrontal cortex.
Definition of the utility of percept-related fMRI – i.e., importance of 
on-line measures of psychophysical data.
Non-dermatomal sensory 
deficits.
Mailis-Gagnon et al., 2003 
[96]
Noxious and non-noxious stimuli were not perceived in these 
dermatomes (Perceived stimuli activated posterior region of the aCG, 
thalamus); but produced decreased signal changes in a number of 
cortical regions (SI, SII, parietal cortex, prefrontal cortex and rostral 
aCG).
Four Patients tested to evaluate nondermatomal neurosensory 
deficits. Another insight into evaluating complex patient groups with 
altered pain processing. fMRI however does provide data in support of 
a testable neurobiological hypothesis instead of generic labeling of 
such patients.
Acupuncture
Electroacupuncture vs. manual 
acupuncture
Napadow et al., 2005 
[97]
For regional responses electroacupuncture>manual>placebo. 
Acupuncture induced increased activations in insula and decreased 
activations in amygdala, hippocampus and cingulated (subgenual and 
retrospelenial), ventromedial prefrontal cortex. No activations were 
seen for tactile control stimulations.
Difficult studies because good controls are so difficult. Process of 
activation of limbic and paralimbic structures may nevertheless be 
highly important in the therapeutic effect in clinical conditions.
Activation of PAG Liu et al., 2004 [98] Mechanical stimulation produced activation in PAG after 20+ min of 
stimulation.
Activation of endogenous analgesic systems may be part of underlying 
effects of acupuncture.
Pain Control
Controllability Salomons et al, 2004 [99] Control attenuated activation in anterior cingulated and insula. Cognitive and affective control of pain has enormous implications in 
clinical aspects of potential painful procedures.
Immediate Control of Brain 
Activation and Pain
deCharms et al., 2005. 
[100]
Real time fMRI (rtfMRI) to train subjects to control activation in 
rACC. Subjects (control and chronic pain) could change activation in 
ACC with corresponding change in perception to noxious stimuli
First use of rtfMRI in pain.
Table 4: Examples of Contributions of fMRI on Endogenous Mechanisms of Pain or Analgesia (Continued)M
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Table 5: Examples of Contributions of fMRI on Analgesics
STUDY FOCUS REFERENCE MAJOR FINDINGS COMMENT
Opioids
Remifentanil(short acting μ opioid) Wise et al., 2004. [101] Activation measured in insula to noxious stimulus in subjects 
receiving Rx.
Study evaluates time course and half life of action of Rx in brain 
region.
Remifentanil Wise et al., 2002 [102] Activation in brain regions to noxious heat stimulus in patients 
receiving Rx vs. saline. Rx produced decrease in level of pain 
activation in insula cortex.
First study to Evaluate CNS effects on stimulus; this allowed for 
extraction of regions most affected by the Rx.
NaloxoneOpioid (μ antagonist) Borras et al., 2004. [59] 10 subjects. Direct drug effects indicated increased in aCG, 
prefrontal cortex, hippocampus and entorrhinal cortex. Post 
infusion painful heat produced increase in activation (correlated 
with psychophysical effects).
First study on opioids to address direct CNS effects. Naloxone 
is a drug that has no cognitive effects in normal healthy 
volunteers.
Morphine (μ agonist) Becerra 2006. [58] Low dose morphine produces changes in reward (SLEA, NAc, 
GOb) endogenous analgesia (PAG), and hypnotic circuits.
fMRI of the effects of morphine on CNS circuits – indicating the 
use of this approach to define specific circuitry activated by a 
drug.
Antiseizure meds
Gabapentin Ianetti et al., 2005 [41] Healthy volunteers. In a capsaicin model, single dose gabapentin 
has an antinociceptive effect but a stronger antihyperalgesic 
effect: the study indicates that the drug is more effective in the 
sensitized state.
An excellent example of the application of fMRI to drug 
evaluation in dissecting the value of a model with potential 
clinical relevance.
Anti-inflammatory
Cyclogoxygenase-2 inhibitor (Cox 
2)
Baliki et al., 2005 [61] Patient with psoriatic arthritis. Single subject evaluation. 
Activation induced by palpating joints included thalamus, insula, 
SI, SII, aCG. Rx produced decrease at 1 h.
An example of specific application on evaluating efficacy of Rx. 
No drug site of action could be detected in this study.
Antidepressant
Amitriptyline Morgan et al., 2005 [62] Evaluation of rectal pain in patients with irritable bowel 
syndrome. Rx produced a decrease in activation in aCG, parietal 
association cortex.
Another example of how the focus on efficacy (CNS) of drugs 
may be evaluated.Molecular Pain 2006, 2:30 http://www.molecularpain.com/content/2/1/30
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These types of studies allow for the interrogation of effects
that may not be obvious (e.g., subcortical, subconscious),
for integration of how drugs may have a role on intact
brain systems that still may be the case in the chronic pain
state, and for the evaluation of potential side effects of
drugs. Our naloxone and morphine studies (see Table 4;
[58,59]) have taken this approach and indicate the ability
to evaluate direct drug effects even when there are no
obvious psychophysical effects (naloxone) or well-
described side effect profiles (morphine) that can be eval-
uated based on circuit activation (e.g., reward, sedation or
analgesic circuits). [59]. The ability to define specific dif-
ferences across classes of drugs (e.g., antidepressants,
membrane stabilizers, opioids) may not only help focus
on common areas of potential mechanisms but also pro-
vide information within different drug classes (e.g., anti-
depressants – tricyclics vs. serotonin norepinehprine
reuptake inhibitors). Advances in this domain should
lead to use of standardized fMRI trials for early phase eval-
uation of pharmacotherapies for pain [60].
Analgesic effects on acute or chronic pain (stimulus-
dependent) – In this group, the effect of the drug is evalu-
ated in subjects usually following an applied painful stim-
ulus. A few examples of this type of approach include the
studies of cyclooxygenase (cox) inhibitors [61] and
amitriptyline [62] in chronic pain conditions and the
effects of drugs on capsaicin-induced hyperalgesia (see
Table 5). These approaches show that pharmacological
evaluation of the CNS effects of drugs is possible, suggest-
ing that fMRI can be used for objective assessments of
drug efficacy; until now, all assessments of analgesic effi-
cacy relied on subjective psychophysical measures.
Conclusion
A revolution in the application of a relatively new technol-
ogy, fMRI, to the field of pain and analgesia is upon us.
Within the next half decade, we should begin to see direct
benefits in the clinical setting that could range from (a)
use of fMRI to evaluate/diagnose a pain condition; (b) use
of fMRI to evaluate drug efficacy in responders vs. non-
responders; (c) use of fMRI to evaluate novel drug efficacy
(the latter will be driven predominantly by the pharma-
ceutical industry) and (d) use of fMRI to provide new
insights into the mechanisms of endogenous 'pain sys-
tems'. We believe there is good reason to expect that the
contribution of this technology together with advances in
other neurosciences will help transition the state of cur-
rent pain therapy from 'o me miserum!' ('o woe is me!')
to more optimistic states for both patient and clinician
'semper aliqud novii' ('always something new' .... and bet-
ter/useful). We believe there is good reason to expect that
the contribution of this technology together with
advances in other neurosciences will significantly advance
therapies for chronic pain and alleviate physical and emo-
tional suffering for the many individuals living with this
disease.
Abbreviation List
aCG – anterior cingulated cortex; CNS – central nervous
system; CRPS – complex regional pain syndrome; DNIC –
Diffuse noxious inhibitory Controls; GOb – Orbitorfron-
tal cortex; Hi – Hippocampus; I – Insula; IBS – irritable
bowel syndrome; NAc – nucleus accumbens; nCF – cunei-
form nucleus; P – putamen; PAG – periaqueductal gray;
pCG – posterior cingulated cortex; Rx – treatment; SCI –
Spinal cord injury; SI – primary somatosensory cortex; SII
– secondary somatosensory cortex; SLEA – sublenticular
extended amygdala; SMP – sympathetically maintained
pain; TG – trigeminal ganglion; TN – trigeminal nucleus;
VAS – visual analogue scale; VMpo – ventromedial
nucleus;
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